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Purpose. Phase I trials of anticancer drugs are commonly conducted using the method of modiﬁed Fibonacci. We have developed
a population-based design for phase I trials of combining anticancer drugs such as irinotecan and carboplatin. Patients and
Methods. Intrapatient dose escalation of irinotecan and carboplatin was performed according to a predetermined schema to reach
individual dose-limiting toxicity (DLT) in 50 patients with solid tumors refractory to previous chemotherapy. The individual
toxicity-limiting dose levels were analyzed for normal distribution using the method of Ryan-Joiner and subsequently used to
determine a population-based maximum tolerated dose (pMTD). For comparison, a simulation study was performed using
the method of modiﬁed Fibonacci. Results. The most common dose-limiting toxicities (DLTs) included neutropenia (58%),
thrombocytopenia(16%),anddiarrhea(8%).Thefrequencyofindividualtoxicity-limitingdoselevelsof50patientsapproximated
a normal distribution. The dose levels associated with individual limiting toxicities ranged from level 1 (irinotecan 100mg/m2 and
carboplatin AUC = 4mg/mL x min) to level 8 (irinotecan 350mg/m2 and carboplatin AUC = 6). The pMTD was determined to
be dose level 3 (150mg/m2 for irinotecan and AUC = 5 for carboplatin). In contrast, the MTD was determined to be dose level
4 (200mg/m2 for irinotecan and AUC 5 for carboplatin) by modiﬁed-Fibonacci simulation. Conclusions. The population-based
design of phase I trial allows optimization of dose intensity and derivation of a pMTD. The pMTD has been applied in phase II
trial of irinotecan and carboplatin in patients with small-cell lung cancer.
Copyright © 2009 Derick Lau et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Phase I clinical trials of new anticancer agents have
been commonly conducted using the method of modiﬁed
Fibonacci [1]. In brief, 3 patients are treated at a starting
dose which is typically one tenth of the dose that is lethal to
10% of animals deﬁned in preclinical studies. If none of the
3 patients experiences DLT, then the next 3 patients will be
treated at the next higher dose. If DLT is observed, additional
patients will be treated at the same or lower dose level to
determine MTD according to a predetermined schema. The
MTD is deﬁned as the highest dose reached for which the
incidence of DLT occurs in less than 33% of the subjects.
Typically, intrapatient dose escalation is not allowed.
There are several shortcomings associated with the
modiﬁed-Fibonacci design. It has long been recognized that
a substantial number of patients are likely to be treated at
subtherapeuticdoses[2,3].Thisisparticularlytruefordrugs
with potential anticancer activity. Since the primary purpose
of phase I trials is to determine DLT and MTD, the eﬃcacy
of the drug may not be evident for certain tumor types
as there are only a small number of patients enrolled into
the trial. Furthermore, the modiﬁed-Fibonacci design does
not take into account individual variations in therapeutic
and toxicologic responses due to genomic polymorphisms
[4, 5]. In addition, since there is a limit of 3 subjects allowed
for each cohort, a waiting period of up to four weeks is
commonly required before enrollment of the next cohort of
subjects. This latter requirement creates anxiety of waiting
for eligible patients.
Several alternative phase I designs have been proposed
which limit the number of patients accrued at each dose
level and accelerate the dose escalation process [1, 6]. There
has also been an increase in the number of clinical trials
that include a component of intrapatient dose escalation
although no formal validation with the modiﬁed-Fibonacci
approach has been reported [7–9]. We have pioneered a
population-based design to maximize therapeutic eﬃcacy,2 Journal of Oncology
to provide preliminary eﬃcacy information and to allow
derivation of a pMTD for subsequent phase II trials.
Irinotecan and cisplatin have been shown to have
promising eﬃcacy in patients with small-cell lung cancer
in phase III trial where irinotecan was given on a weekly
schedule [10]. We wished to perform a population-based
phase I trial of irinotecan, given every 3 weeks, and
carboplatin, a platinated anticancer drug which is generally
better tolerated than its cisplatin analog.
2. Methods
2.1. Patients and Intrapatient Dose Escalation. Eligibility
criteria included patients with a diagnosis of advanced
solid tumor not curable by standard therapies; measur-
able disease; Zubrod performance status of 0–2; age >18
years; prior chemotherapy was allowed except irinotecan
or carboplatin; adequate hematologic (ANC >1500 and
platelets >100000/mL), hepatic (total bilirubin and SGOT
<2× upper limit of normal), and renal (serum creatinine
<1.5mg/dl) functions. All patients signed informed consent
in accordance with guidelines of the institutional review
board.
Intrapatient dose-escalation schema is shown in Table 1.
This schema was extrapolated from the results of a previous
population-based phase I trial of irinotecan and epirubicin
in patients with solid tumors, in which the pMTD was
determined to be 100mg/m2 for irinotecan and 50mg/m2
for epirubicin in previously chemotherapy-treated patients
[11]. All patients were started at dose level 3, which consisted
of irinotecan, 150mg/m2, infused intravenously over 90
minutes, and carboplatin, AUC 5mg/mL × min, given as
an intravenous bolus on day 1. The carboplatin dose was
determined according to the Calvert formula [12]a n da
calculated creatinine clearance [13]. Toxicity was graded
according to the common toxicity criteria, Version 2, of the
National Cancer Institute (NCI). Treatment was repeated
every 21 days and the dose for subsequent cycle was escalated
by one dose level as outlined in Table 1 if no grade III or
IV toxicity was observed. For any grade IV neutropenia,
grade III or IV thrombocytopenia, or grade III or IV
nonhematologic toxicity, the dose was decreased by one level
as outlined in Table 1. No prophylactic growth factor was
allowed. Patients remained on treatment for at least 6 cycles,
oruntiltherewasevidenceofdiseaseprogression,intolerable
toxicity, or voluntary withdrawal.
In accordance to common practice, DLT was deﬁned as
grade III or IV thrombocytopenia, grade IV neutropenia, or
any grade III or IV nonhematologic toxicity. Similar to the
modiﬁed-Fibonacci method [1], the pMTD was deﬁned as
the highest dose level that caused DLT in less than 33% of the
population studied (DLT33%). For each subject who did not
reach DLT, the dose level associated with DLT was assumed
to be one level higher than the last one the subject received
prior to coming oﬀ the study.
Responses were evaluated after 3 cycles of treatment.
Tumor measurement was performed according to the NCI
RECIST criteria [14].
Table 1: Schema of dose levels for irinotecan and carboplatin.
Dose level Irinotecan (mg/m2) Carboplatin AUC
1 100 4
2 100 5
3 150 5
4 200 5
5 250 5
6 250 6
7 300 6
8 350 6
2.2. Statistical Analysis. Based on the results of a previous
population-based phase I trial of irinotecan and epirubicin,
t h eo p t i m a ln u m b e ro fs u b j e c t sw a se s t i m a t e dt ob e2 5t o5 0
for reaching a Gaussian or normal distribution of individual
toxicity-limiting dose levels [11]. The computer program
of Ryan-Joiner test (Minitab Release 14, statistical software
for Windows, Minitab Inc., State College, Pa, USA) was
employed to determine the normality of the distribution of
individual toxicity-limiting dose levels [15]. In the Ryan-
Joiner analysis, a correlation coeﬃcient, r, was obtained to
determine the degree of normality. The more closer was r to
1, the more normal was the distribution
r =

Yibi 
s2(n − 1)

b2
i
,( 1 )
whereYi wasanindividualtoxicity-limitingdoselevel,bi was
the probability percentage point of the normal distribution
associated with the individual dose level, s denoted the
sample variance, and n was the sample size.
To determine the pMTD, the mean (MDLT) and standard
deviation (SDDLT) of the 50 individual dose levels associated
with DLT were calculated. The pMTD was the estimated
highest dose level that caused DLT in less than 33% of
the subjects (DLT33%). Assuming that the individual DLT
followedanormaldistribution,the33%cutoﬀpointwasjust
below 17% to the left from the mean. Therefore,
DLT33% = MDLT −

SDDLT ×Z17%

,( 2 )
where Z17% is the level of standard deviation to the left of the
MDLT with a probability of 17% under a normal distribution
curve [16]. Thus, the pMTD would be one dose level lower
than DLT33%.
2.3. Modiﬁed-Fibonacci Simulation. To compare the pMTD
derived from the population-based approach with the MTD
that otherwise would have been obtained with the modiﬁed-
Fibonacci method, a simulation exercise was performed
using the data from the current study. The Fibonacci
simulation would also allow us to compare the number
of subjects required using each approach. The procedures
for simulation were performed according to the 3 + 3 rule
of modiﬁed Fibonacci [1] with the following assumptions.
(1) The ﬁrst cohort of subjects started at dose level 3;
(2) if a patient treated at a particular dose level had notJournal of Oncology 3
Table 2: Patient characteristics.
Number of patients 50
Male/female 27/23
Age (yr)
range 35–83
Median 61
Performance status
01 2
13 5
23
Number of previous chemotherapies
12 5
22 0
35
Tumor types
Nonsmall-cell lung 21
Small-cell lung 10
Gastrointestinal 10
Head/neck 3
Miscellaneous 6
Table 3: Dose-limiting grade III/IV toxicities (N = 50).
Toxicities Number of patients (%)
Neutropenia 29 (58)
Thrombocytopenia 8 (16)
Diarrhea 4 (8)
Nausea/emesis 4 (8)
Asthenia 2 (4)
experienced DLT, it was assumed that no DLT would have
been experienced at a lower starting dose; (3) if a patient had
experienced DLT at a particular dose level, it was assumed
thatthispatientwouldhaveexperiencedDLTatahigherdose
level; (4) the MTD is deﬁned as the highest dose reached for
which the incidence of DLT is less than 33% in the subjects
[1].
3. Results
3.1. Patient Characteristics. A total of 50 patients were
enrolled from a single institution within a period of 24
months. Patient characteristics are summarized in Table 2.
There were 27 male and 23 female patients. The median
age was 61 years with a range of 35–83 years. Forty-seven
patients (94%) had a Zubrod performance status of 0 or
1. All the patients had previously received at least one
regimen of chemotherapy and the mean number of previous
chemotherapy regimens was 1.6 (range 1 to 3). Forty-two
percent of the patients had a diagnosis of nonsmall-cell
lung cancer, 20% with small-cell lung cancer, 20% with
gastrointestinal cancer, 6% with head/neck cancer, and 12%
with a variety of solid cancers.
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Figure 1: Distribution of individual dose levels associated with
dose-limitingtoxicity(DLT)ofirinotecanandcarboplatin(N =50).
3.2. Derivation of Population-Based MTD. Among the 50
patients enrolled, the median number of cycles of irinotecan
and carboplatin, that had been delivered, was three. Treat-
ment was discontinued before reaching DLT in 10 patients
due to disease progression or voluntary withdrawal. Dose
escalation to DLT was achieved in the remaining 40 patients.
AsshowninTable 3,themostcommongradeIII/IVtoxicities
or dose-limiting toxicities were neutropenia in 58%, throm-
bocytopenia in 16%, diarrhea in 8%, nausea/emesis in 8%,
and asthenia in 4% of the patients.
The distribution of individual toxicity-limiting dose
levelsrangedfromlevel1(100mg/m2 ofirinotecanandAUC
4ofcarboplatin)tolevel8(irinotecan350mg/m2 andcarbo-
platin AUC 6) as shown in Figure 1. The individual toxicity-
limiting dose levels approximated a normal distribution with
a correlation coeﬃcient, r, of 0.992, based on the Ryan-
Joiner analysis. The cumulative percentage of subjects with
increasing toxicity-limiting dose levelsareshown inFigure 2.
Assuming a normal distribution of the toxicity-limiting dose
levels, the DLT33% was calculated to be 3.9. By the deﬁnition
that pMTD was one dose level lower than that of DLT33%,
the pMTD was thus 2.9 which approximated 150mg/m2 of
irinotecan and AUC 5 of carboplatin.
Fortyofthe50patientswereassessableforresponses.Ten
patients were not assessable for response due to early disease
progression or withdrawal from the study before having
received 3 cycles of treatment. The best responses by tumor
type are shown in Table 4. Of note, the response rate was
40% for small-cell lung cancer, 24% for nonsmall-cell lung
cancer, and 30% for gastrointestinal malignancies consisting
mainly of esophageal and gastric cancers. There was no
apparent correlation between response rate and individual
MTD levels.
3.3. Modiﬁed-Fibonacci Simulation. By the Fibonacci simu-
lation, an MTD of dose level 4 (200mg/m2 of irinotecan and
AUC 5 of carboplatin) was derived after simulation of 18
consecutive patients.4 Journal of Oncology
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Figure 2:Cumulativepercentofpatientsexperienceddose-limiting
toxicity (DLT) with increasing dose levels of irinotecan and
carboplatin (N = 50).
Table 4: Tumor types and best response to treatment. PR: partial
response; SD: stable disease; PD: progressive disease; NA: not
assessable.
Tumor types Number of patients
T o t a lP RS DP DN A
Nonsmall-cell lung 21 5 7 3 6
Small-cell lung 10 4 3 2 1
Gastrointestinal 10 3 3 2 2
Head and neck 3 0 1 2 0
Miscellaneous 6 1 3 1 1
Total 50 13 17 10 10
Table 5: Comparison of features of population based versus
modiﬁed-Fibonacci method in phase I trials.
Features Population based Fibonacci
Number of patients required ∼50 ∼20
Enrollment of patients Continuous Cohorts of three
Waiting time between cohorts None Required
Eﬃcacy optimized Yes No
Preliminary eﬃcacy data Yes Yes/No
Table 5 outlines the features of the population-based
approach versus the modiﬁed-Fibonacci method.
4. Discussion
Inthisstudy,wehavedemonstratedthefeasibilityofapplying
a population-based approach in conducting phase I trial and
the derivation of a pMTD for irinotecan and carboplatin for
subsequent phase II trials.
This study clearly illustrated the phenomenon of pop-
ulation polymorphism in clinical practice. We showed that
the individual DLTs occurred over a range of 8 dose levels.
At dose level 1, the dose for irinotecan was 100mg/m2 and
carboplatin was AUC of 4. At dose level 8, the corresponding
doses were 350 mg/m2 and AUC of 6, respectively. It is quite
remarkable to see that one patient could tolerate 3.5 times
higher of irinotecan and 1.5 times higher of carboplatin than
another patient. This marked degree of interpatient dose
variation was most likely due to interpatient variability in
pharmacogenomics. In this regard, irinotecan is a typical
example with individual variability in pharmacokinetics and
toxicity. Following intravenous administration, irinotecan
is converted to an active metabolite, SN-38, which is
subsequently deactivated by uridine diphosphate glucurono-
syltransferase isoform 1A1 (UGT1A1). It has been demon-
strated that variability in pharmacokinetics and toxicity of
irinotecan correlates with polymorphisms of the UGT1A1
promoter [17, 18]. In this study, we did not monitor
the pharmacokinetics of irinotecan or pharmacogenetics of
UGT1A1.Nevertheless,webelievethattheintrapatientdose-
escalationschemeisappropriate forconductingphaseItrials
with a drug such as irinotecan.
Maximum tolerated doses of carboplatin and irinotecan
have been reported in previous phase I trials although
irinotecan typically was administered on a weekly schedule
in these studies. Based on phase I trial on patients with
relapsed or refractory advanced malignancies as reported by
Jones et al., the MTD was irinotecan at 60mg/m2 on days 1
and 8 in combination with carboplatin at AUC 4.0 on day 1
for 28-day cycles [19]. In another phase 1 trial on subjects
with ovarian cancer previously treated with cisplatin-based
chemotherapy, Yonemori et al. reported that the MTD of the
irinotecan/carboplatin combination was 60mg/m2 on days
1, 8, and 15, and 5mgmL/minute on day 1, respectively, for
28-day cycles [20]. Undoubtedly, the delivery of the 3-week
r e g i m e na sr e p o r t e di no u rs t u d yi sm o r ec o n v e n i e n ta n d
presumably less costly.
In phase I trials employing the modiﬁed-Fibonacci
design, the initial cohorts of subjects are commonly given
subtherapeutic doses of an anticancer drug. On the other
hand, some subjects in the subsequent cohorts may receive
toxic doses as dose escalation is based on the 3 + 3 rule [1].
In the intrapatient dose-escalation design, each subject is
started on a low dose and is entitled to receive a higher dose
as long as there is no DLT. Thus, this latter approach tends to
minimize toxicity and maximize eﬃcacy in each subject.
In traditional phase I trials, only 3 subjects can be
e n r o ll e da tad o s el ev e la to n et i m e .G e n e ra ll y ,t h eyh a v et ob e
observed for a month before the next cohort of subjects can
be enrolled at the next dose level. This requirement results in
unnecessary waiting for potentially eligible patients and may
prolong the conduct of a study. With the population-based
method, subjects commonly can be enrolled continuously to
a study without a mandatory waiting period.
There are potential disadvantages associated with the
population-based design. A patient may develop progressive
diseaseorleavethestudyforotherreasonsbeforesubsequent
dose escalation and determination of DLT can be achieved.
Dose escalation in the same patient may result in cumulative
toxicity and, theoretically, an MTD level lower than that
obtained with the Fibonacci method. However, in our study,
the DLTs were reached with the 3 lowest dose levels in
more than 50% of subjects. In addition, there were subjects
who tolerated more than 4 sequentially escalated dosesJournal of Oncology 5
without experiencing obvious cumulative toxicity. These
observations indicate that the intolerance to treatment is
intrinsic to each subject rather than due to cumulative
toxicity.
With a population-based approach, it is apparent that
a larger number of subjects are required than that for the
modiﬁed-Fibonacci design. In our study, we had enrolled 50
s u b j e c t st od e r i v eap M T D .I nc o m p a r i s o n ,o n l y1 8s u b j e c t s
would have been needed with the Fibonacci simulation.
With a limitation of the number of subjects, it may yield
a MTD not representative of a population. Based on the
results of Ryan-Joiner analysis and pMTDs, we estimated
that 40 patients would have been adequate to obtain similar
results with the population-based approach. With a larger
number of patients having a variety of tumor types, however,
it provides a better opportunity to evaluate eﬃcacy in a
certain tumor type. For example, in our study, we observed
partial response in 4 of 10 patients with relapsed small-
cell lung cancer. This observation has led to phase II trial
which employed the pMTD of irinotecan (150mg/m2)a n d
carboplatin (AUC = 5) derived in this study in patients with
relapsed small-cell lung cancer [21].
The population-based design is open ended in regard
to the number of patients to be accrued and dose levels
to be escalated. This design appears most appropriate for a
combination of anticancer drugs with proven single-agent
anticancer activity and toxicity. It may not be appropriate
for anticancer drugs with low toxicity proﬁles such as the
molecular-targeting agents.
We conclude that the population-based design is a
feasible approach for conducting phase I trials of anticancer
drugs. This approach allows derivation of a pMTD without
causing obvious cumulative toxicity.
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